Role of genes linked to sporadic Alzheimer's disease risk in the production of β-amyloid peptides

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 38, 2012, Pages 15307-15311

  Bali, Jitin ^a   Gheinani, Ali Hashemi ^a   Zurbriggen, Sebastian ^a   Rajendran, Lawrence ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cystatin; Epistasis; Genome wide association studies; Late onset

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1;

ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GENE FUNCTION; GENE SILENCING; GENETIC RISK; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RNA INTERFERENCE;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL PROLIFERATION; CYSTATINS; EPISTASIS, GENETIC; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HELA CELLS; HUMANS; MODELS, GENETIC; MUTATION; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RISK; RNA INTERFERENCE;

EID: 84866530316     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201632109     Document Type: Article

References (37)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimer's Dementia 3:186-191. (Pubitemid 46825511)
2. Frisoni GB, Hampel H, O'Brien JT, Ritchie K, Winblad B (2011) Revised criteria for Alzheimer's disease: What are the lessons for clinicians? Lancet Neurol 10:598-601.
3. Ankarcrona M, Mangialasche F, Winblad B (2010) Rethinking Alzheimer's disease therapy: Are mitochondria the key? J Alzheimers Dis 20(Suppl 2):S579-S590.
4. Small SA, Gandy S (2006) Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron 52:15-31. (Pubitemid 44466354)
5. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9:702-716.
6. De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev 90:465-494.
7. Rajendran L, Annaert W (2012) Membrane trafficking pathways in Alzheimer's disease. Traffic 13:759-770.
8. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 30:14946-14954.
9. Herrup K (2010) Reimagining Alzheimer' s disease-an age-based hypothesis. J Neurosci 30:16755-16762.
10. Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787-12794.
11. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615-29619.
12. Spasic D, Annaert W (2008) Building gamma-secretase: The bits and pieces. J Cell Sci 121:413-420.
13. Borchelt DR, et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005-1013. (Pubitemid 26424026)
14. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256:184-185.
15. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 39:17-23. (Pubitemid 46026496)
16. Harold D, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088-1093.
17. Hollingworth P, et al.; Alzheimer' s Disease Neuroimaging Initiative; CHARGE Consortium; EADI1 Consortium (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43:429-435.
18. Duff K, et al. (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713. (Pubitemid 26360645)
19. Rajendran L, et al. (2008) Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 320:520-523. (Pubitemid 351590663)
20. Rajendran L, et al. (2006) Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 103:11172-11177. (Pubitemid 44156491)
21. De Strooper B, Vassar R, Golde T (2010) The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6:99-107.
22. Mi W, et al. (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39:1440-1442. (Pubitemid 350191347)
23. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ (2009) Epistasis in sporadic Alzheimer's disease. Neurobiol Aging 30:1333-1349.
24. Belbin O, et al. (2011) Investigation of 15 of the top candidate genes for late-onset Alzheimer's disease. Hum Genet 129:273-282.
25. Hunter S, Friedland RP, Brayne C (2010) Time for a change in the research paradigm for Alzheimer's disease: The value of a chaotic matrix modeling approach. CNS Neurosci Ther 16:254-262.
26. Irizarry MC, et al. (2000) Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann N Y Acad Sci 920:171-178. (Pubitemid 32056566)
27. DeMattos RB, et al. (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 99:10843-10848.
28. El Khoury J, et al. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432-438. (Pubitemid 46559828)
29. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2:605-613. (Pubitemid 37162569)
30. Mawuenyega KG, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330:1774.
31. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17:1060-1065.
32. Seabrook GR, Ray WJ, Shearman M, Hutton M (2007) Beyond amyloid: The next generation of Alzheimer' s disease therapeutics. Mol Interv 7:261-270. (Pubitemid 47607486)
33. Sperling RA, Jack CR, Jr., Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Trans Med 3:111-133.
34. Schneider LS, Lahiri DK (2009) The perils of Alzheimer's drug development. Curr Alzheimer Res 6:77-78.
35. Sambamurti K, et al. (2011) Targets for AD treatment: Conflicting messages from γ-secretase inhibitors. J Neurochem 117:359-374.
36. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer' s disease pathophysiology. Biochim Biophys Acta 1802:2-10.
37. Treusch S, et al. (2011) Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334:1241-1245.